Research programme: pegylated therapeutics - Belrose Pharma

Drug Profile

Research programme: pegylated therapeutics - Belrose Pharma

Alternative Names: EZN 3008; PEG C1 esterase inhibitor; Pegylated anti-TNF-α antibody; Pegylated C1 esterase inhibitor; Pegylated interferon-β-1b - Enzon

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Belrose Pharma; Enzon Pharmaceuticals
  • Class Antibodies; Drug conjugates; Interferons; Oligonucleotides; Peptides; Proteins; Small molecules
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Hereditary angioedema; Multiple sclerosis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (IV)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (SC)
  • 15 Jul 2013 Research programme: pegylated therapeutics - Belrose Pharma is available for licensing as of 15 Jul 2013. http://belrosepharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top